Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 14/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22398651 | 0.84 | MEN1 (0.47) | MEN1KMT2ATLR2PLK1CA2 | |
| SCHEMBL22398650 | 0.84 | MEN1 (0.47) | MEN1KMT2ATLR2PLK1CA2 | |
| SCHEMBL30951032 | 0.81 | MAPK1 (0.30) | — | |
| SCHEMBL27252651 | 0.81 | HRH2 (0.30) | TLR2 | |
| SCHEMBL22687577 | 0.79 | MEN1 (0.43) | MEN1KMT2ATLR2PLK1CA2 | |
| SCHEMBL25383656 | 0.76 | MEN1 (0.40) | MEN1KMT2ATLR2CA2 | |
| SCHEMBL12446030 | 0.76 | TDP1 (0.47) | MEN1KMT2ACA2 | |
| SCHEMBL25874232 | 0.76 | MEN1 (0.38) | MEN1KMT2ATLR2PLK1CA2 | |
| SCHEMBL25030519 | 0.75 | CA2 (0.42) | MEN1KMT2ATLR2CA2 | |
| SCHEMBL22398629 | 0.74 | MEN1 (0.41) | MEN1KMT2ATLR2PLK1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016918-B2 | Peptide-containing adjuvant compounds having peg spacers | UNIVERSITEIT LEIDEN (NL) | 2024-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016918-B2 | Peptide-containing adjuvant compounds having peg spacers | MYD88, CD74, NGLY1 | MEN1 1184/4885KMT2A 3733/4885TLR2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.